ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by ValuEngine

Share on StockTwits

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday, ValuEngine reports.

Several other analysts also recently commented on ANIP. Guggenheim began coverage on shares of ANI Pharmaceuticals in a research report on Thursday, September 12th. They set a “buy” rating and a $76.00 price objective for the company. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 22nd. Finally, Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $85.00.

ANI Pharmaceuticals stock traded down $4.05 during trading hours on Thursday, reaching $57.38. 388,900 shares of the stock were exchanged, compared to its average volume of 137,916. The stock has a 50 day moving average of $73.65 and a two-hundred day moving average of $73.58. The company has a market cap of $954.49 million, a P/E ratio of 12.45 and a beta of 2.20. ANI Pharmaceuticals has a twelve month low of $36.92 and a twelve month high of $86.96. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.20). The firm had revenue of $51.30 million for the quarter, compared to analyst estimates of $56.10 million. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.29 EPS. On average, analysts expect that ANI Pharmaceuticals will post 5.29 earnings per share for the current fiscal year.

In other ANI Pharmaceuticals news, major shareholder Meridian Venture Partners Ii L sold 9,315 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $69.34, for a total transaction of $645,902.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 78,591 shares of company stock worth $5,582,839. Company insiders own 24.70% of the company’s stock.

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth $32,000. Usca Ria LLC purchased a new stake in ANI Pharmaceuticals in the third quarter worth $34,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in ANI Pharmaceuticals by 237.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock worth $65,000 after purchasing an additional 559 shares during the period. Robeco Institutional Asset Management B.V. purchased a new stake in ANI Pharmaceuticals in the third quarter worth $92,000. Finally, Convergence Investment Partners LLC purchased a new stake in ANI Pharmaceuticals in the second quarter worth $164,000. Institutional investors and hedge funds own 70.97% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Recommended Story: How does a 12b-1 fee affect fund performance?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Communications Systems  Trading Up 9.1%
Communications Systems Trading Up 9.1%
ANI Pharmaceuticals  Downgraded by ValuEngine
ANI Pharmaceuticals Downgraded by ValuEngine
Neos Therapeutics  Stock Price Up 11.7% on Earnings Beat
Neos Therapeutics Stock Price Up 11.7% on Earnings Beat
Melco Resorts & Entertainment  Upgraded to Buy by Zacks Investment Research
Melco Resorts & Entertainment Upgraded to Buy by Zacks Investment Research
Analysts Set United Continental Holdings Inc  Price Target at $103.64
Analysts Set United Continental Holdings Inc Price Target at $103.64
Lumber Liquidators  Cut to Sell at Zacks Investment Research
Lumber Liquidators Cut to Sell at Zacks Investment Research


 
© 2006-2019 Zolmax.